131 related articles for article (PubMed ID: 37167681)
1. Peripheral changes in T cells predict efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer.
Lao J; Xu H; Liang Z; Luo C; Shu L; Xie Y; Wu Y; Hao Y; Yuan Y
Immunobiology; 2023 May; 228(3):152391. PubMed ID: 37167681
[TBL] [Abstract][Full Text] [Related]
2. CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-PD-1 immunotherapy.
Qu J; Wu B; Chen L; Wen Z; Fang L; Zheng J; Shen Q; Heng J; Zhou J; Zhou J
J Exp Clin Cancer Res; 2024 May; 43(1):134. PubMed ID: 38698468
[TBL] [Abstract][Full Text] [Related]
3. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
4. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
5. OX40 enhances T cell immune response to PD-1 blockade therapy in non-small cell lung cancer.
Lao J; Cao C; Niu X; Deng S; Ming S; Liang S; Shang Y; Yuan Y; Shi X; Liang Z; Wu M; Wu Y
Int Immunopharmacol; 2022 Jul; 108():108813. PubMed ID: 35580452
[TBL] [Abstract][Full Text] [Related]
6. The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.
Mazzaschi G; Facchinetti F; Missale G; Canetti D; Madeddu D; Zecca A; Veneziani M; Gelsomino F; Goldoni M; Buti S; Bordi P; Aversa F; Ardizzoni A; Quaini F; Tiseo M
Lung Cancer; 2019 Jan; 127():153-163. PubMed ID: 30642544
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy.
Shi L; Lu J; Zhong D; Song M; Liu J; You W; Li WH; Lin L; Shi D; Chen Y
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657812
[TBL] [Abstract][Full Text] [Related]
8. Expression of PD1 and BTLA on the CD8
Bao Y; Mo JF; Wu JY; Cao CX
Chin Med Sci J; 2019 Nov; 34(4):248-255. PubMed ID: 33906710
[No Abstract] [Full Text] [Related]
9. Dynamic immune signatures of patients with advanced non-small-cell lung cancer for infection prediction after immunotherapy.
Luo YH; Shen CI; Chiang CL; Huang HC; Chen YM
Front Immunol; 2024; 15():1269253. PubMed ID: 38343550
[TBL] [Abstract][Full Text] [Related]
10. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
11. CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer.
Olingy C; Alimadadi A; Araujo DJ; Barry D; Gutierrez NA; Werbin MH; Arriola E; Patel SP; Ottensmeier CH; Dinh HQ; Hedrick CC
Front Immunol; 2022; 13():842653. PubMed ID: 35493454
[TBL] [Abstract][Full Text] [Related]
12. [Effect of Pembrolizumab on T Lymphocyte Subsets in Patients with Advanced
Non-small Cell Lung Cancer and Its Therapeutic Effect].
Wang Y; Wang Y; Jiang M; Zhao Y; Zhang X
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):182-187. PubMed ID: 33819968
[TBL] [Abstract][Full Text] [Related]
13. Dynamic changes in circulating PD-1
Kim CG; Hong MH; Kim KH; Seo IH; Ahn BC; Pyo KH; Synn CB; Yoon HI; Shim HS; Lee YI; Choi SJ; Lee YJ; Kim EJ; Kim Y; Kwak JE; Jung J; Park SH; Paik S; Shin EC; Kim HR
Eur J Cancer; 2021 Jan; 143():113-126. PubMed ID: 33302114
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy.
Leung EL; Li RZ; Fan XX; Wang LY; Wang Y; Jiang Z; Huang J; Pan HD; Fan Y; Xu H; Wang F; Rui H; Wong P; Sumatoh H; Fehlings M; Nardin A; Gavine P; Zhou L; Cao Y; Liu L
Nat Commun; 2023 Aug; 14(1):5115. PubMed ID: 37607911
[TBL] [Abstract][Full Text] [Related]
15. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
16. Immunomodulatory Effect of Lentinan on Aberrant T Subsets and Cytokines Profile in Non-small Cell Lung Cancer Patients.
Wang XE; Wang YH; Zhou Q; Peng M; Zhang J; Chen M; Ma LJ; Xie GM
Pathol Oncol Res; 2020 Jan; 26(1):499-505. PubMed ID: 30460541
[TBL] [Abstract][Full Text] [Related]
17. MAIT cells are associated with responsiveness to neoadjuvant immunotherapy in COPD-associated NSCLC.
Yin Y; Zeng A; Abuduwayiti A; Xu Z; Chen K; Wang C; Fang X; Wang J; Jiang G; Dai J
Cancer Med; 2024 Mar; 13(6):e7112. PubMed ID: 38509769
[TBL] [Abstract][Full Text] [Related]
18. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
[TBL] [Abstract][Full Text] [Related]
19. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
20. [Expression levels of co-inhibitory molecules CTLA-4, LAG-3, PD-1 and CD39 on CD4⁺ T cells correlate with progression of non-small cell lung cancer].
Wei T; Zhang J; Wu Y; Zhang D; Lu L; Shen Q
Zhonghua Zhong Liu Za Zhi; 2014 Jun; 36(6):424-9. PubMed ID: 25241783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
